Leukemia, Myelocytic, Acute | Hematologic Neoplasms Absent | MYELODYSPLASTIC SYNDROME Absent | Myeloproliferative disease Absent
Item
diagnosis of aml with no history of previous clonal/malignant hematologic disorders such as myelodysplastic syndromes or myeloproliferative disorders.
boolean
C0023467 (UMLS CUI [1])
C0376545 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C3463824 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0027022 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Patients Newly Diagnosed | Age
Item
newly diagnosed patients will be age 70 or older
boolean
C0030705 (UMLS CUI [1,1])
C1518321 (UMLS CUI [1,2])
C0001779 (UMLS CUI [2])
Recurrent disease | Age | Status post First Relapse | Patient Inappropriate Salvage Chemotherapy
Item
relapses patients will be age 60 or older any time following first relapse, if patient is not considered candidate/not interested in salvage chemotherapy.
boolean
C0277556 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0231290 (UMLS CUI [3,1])
C4054953 (UMLS CUI [3,2])
C0030705 (UMLS CUI [4,1])
C1548788 (UMLS CUI [4,2])
C0085405 (UMLS CUI [4,3])
C0392920 (UMLS CUI [4,4])
Refractory Disease | Age | Chemotherapy Failed | Induction Chemotherapy Failed | Salvage Chemotherapy Failed
Item
refractory disease patients will be age 18-59 who have failed at least 2 lines of conventional chemotherapy (1 induction and 1 salvage)
boolean
C1514815 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0392920 (UMLS CUI [3,1])
C0231175 (UMLS CUI [3,2])
C3179010 (UMLS CUI [4,1])
C0231175 (UMLS CUI [4,2])
C0085405 (UMLS CUI [5,1])
C0392920 (UMLS CUI [5,2])
C0231175 (UMLS CUI [5,3])
Prior Therapy Discontinued AML | Adverse effects Due to Therapy | Patient recovered
Item
patient must have discontinued all previous therapies for aml at least 14 days and recovered from the non-hematologic side effects of the therapy.
boolean
C1514463 (UMLS CUI [1,1])
C1444662 (UMLS CUI [1,2])
C0023467 (UMLS CUI [1,3])
C0879626 (UMLS CUI [2,1])
C0678226 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C1115804 (UMLS CUI [3])
Laboratory tests Consistent with Study Protocol
Item
laboratory tests must be within protocol-specified ranges
boolean
C0022885 (UMLS CUI [1,1])
C0332290 (UMLS CUI [1,2])
C2348563 (UMLS CUI [1,3])
Able to swallow Oral Medication
Item
patient must be able to swallow and tolerate oral medication.
boolean
C2712086 (UMLS CUI [1,1])
C0175795 (UMLS CUI [1,2])
Central nervous system leukemia | Cerebrospinal Fluid Cytology | Flow Cytometry | Imaging
Item
patients with known central nervous system (cns) leukemia by spinal fluid cytology, flow cytometry or imaging.
boolean
C1332884 (UMLS CUI [1])
C0007806 (UMLS CUI [2,1])
C1305671 (UMLS CUI [2,2])
C0016263 (UMLS CUI [3])
C0011923 (UMLS CUI [4])
Hematological Disease | MYELODYSPLASTIC SYNDROME | Myeloproliferative disease
Item
history of antecedent pre-leukemic hematologic disorders such as myelodysplastic syndromes or myeloproliferative disorders.
boolean
C0018939 (UMLS CUI [1])
C3463824 (UMLS CUI [2])
C0027022 (UMLS CUI [3])
Acute Promyelocytic Leukemia
Item
diagnosis of acute promyelocytic leukemia (apl)
boolean
C0023487 (UMLS CUI [1])
Anticoagulation Therapy chronic required | Tobacco use | rifabutin | rifapentine | phenytoin | carbamazepine | phenobarbital | St. John's wort extract
Item
patients who require chronic anticoagulation, are current smokers or who are taking rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital and st. john's wort are not eligible.
boolean
C0003281 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C1514873 (UMLS CUI [1,3])
C0543414 (UMLS CUI [2])
C0140575 (UMLS CUI [3])
C0073372 (UMLS CUI [4])
C0031507 (UMLS CUI [5])
C0006949 (UMLS CUI [6])
C0031412 (UMLS CUI [7])
C0813171 (UMLS CUI [8])
Corneal erosion | Corneal Sensitivity Abnormal
Item
patients with active corneal erosions or history of abnormal corneal sensitivity test.
boolean
C0392163 (UMLS CUI [1])
C1707516 (UMLS CUI [2,1])
C0205161 (UMLS CUI [2,2])
Illness Serious | Communicable Disease | Congestive heart failure New York Heart Association Classification | Angina, Unstable | New onset Angina Pectoris | Myocardial Infarction | Ventricular arrhythmia Requirement Anti-Arrhythmia Agents | Cerebrovascular accident | Mental disorder Limiting Protocol Compliance
Item
patients with serious illness such as: significant ongoing or active infection, new york heart association (nyha) grade ii or greater congestive heart failure, unstable angina (anginal symptoms at rest), new onset angina (began within the last 3 months), myocardial infarction within the past 6 months, cardiac ventricular arrhythmias requiring anti-arrhythmic therapy, cerebrovascular accident within past 3 months, or psychiatric illness that would limit compliance with the study requirements.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0018802 (UMLS CUI [3,1])
C1275491 (UMLS CUI [3,2])
C0002965 (UMLS CUI [4])
C0746890 (UMLS CUI [5,1])
C0002962 (UMLS CUI [5,2])
C0027051 (UMLS CUI [6])
C0085612 (UMLS CUI [7,1])
C1514873 (UMLS CUI [7,2])
C0003195 (UMLS CUI [7,3])
C0038454 (UMLS CUI [8])
C0004936 (UMLS CUI [9,1])
C0439801 (UMLS CUI [9,2])
C0525058 (UMLS CUI [9,3])